Antonio Gallardo-Pizarro
Overview
Explore the profile of Antonio Gallardo-Pizarro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
1
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
COVID-19 Patients Benefitting From Remdesivir for Improved Survival: A Neural Network-Based Approach
Garcia-Vidal C, Teijon-Lumbreras C, Aiello T, Chumbita M, Menendez R, Subira A, et al.
J Med Virol
. 2025 Mar;
97(3):e70276.
PMID: 40059457
Conflicting results from randomized trials regarding the efficacy of remdesivir for COVID-19 have been reported. We aimed to develop a neural network (NN) to identify COVID-19 patients who would derive...
2.
Chumbita M, Peyrony O, Teijon-Lumbreras C, Monzo-Gallo P, Aiello T, Gallardo-Pizarro A, et al.
Int J Infect Dis
. 2025 Mar;
153:107848.
PMID: 40043678
No abstract available.
3.
Gallardo-Pizarro A, Teijon-Lumbreras C, Monzo-Gallo P, Aiello T, Chumbita M, Peyrony O, et al.
Antibiotics (Basel)
. 2025 Jan;
14(1).
PMID: 39858299
The rise of multidrug-resistant (MDR) infections demands personalized antibiotic strategies for febrile neutropenia (FN) in hematological malignancies. This study investigates machine learning (ML) for identifying patient profiles with increased susceptibility...
4.
Lopera C, Monzo P, Aiello T, Chumbita M, Peyrony O, Gallardo-Pizarro A, et al.
Microbiol Spectr
. 2024 Aug;
12(10):e0296123.
PMID: 39194256
Importance: Multidrug-resistant (MDR) bacteria pose a global public health threat as they are more challenging to treat, and they are on the rise. Solid cancer patients are often immunocompromised due...
5.
Peyrony O, Garcia-Pouton N, Chumbita M, Teijon-Lumbreras C, Aiello T, Monzo-Gallo P, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae398.
PMID: 39070045
Background: This study aimed to describe documented infections associated with postinfusion fever after CAR T-cell therapy and to evaluate daily changes in vital signs, laboratory results, and the National Early...
6.
Gras E, Aiello T, Chumbita M, Gallardo-Pizarro A, Monzo-Gallo P, Teijon-Lumbreras C, et al.
J Antimicrob Chemother
. 2024 Jul;
79(9):2364-2368.
PMID: 38985649
Objectives: To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined. Methods: We conducted a retrospective evaluation of...
7.
Monzo-Gallo P, Alastruey-Izquierdo A, Chumbita M, Aiello T, Gallardo-Pizarro A, Peyrony O, et al.
Infection
. 2024 May;
52(5):1651-1656.
PMID: 38801514
Objectives: We aimed to report the emergence of azole-resistant invasive aspergillosis in hematologic patients admitted to a tertiary hospital in Spain during the last 4 months. Methods: Prospective, descriptive study...
8.
Gallardo-Pizarro A, Campos-Rodriguez V, Martin-Iglesias D, Ruiz-Irastorza G
Int J Rheum Dis
. 2024 Apr;
27(4):e15143.
PMID: 38576108
Aim: This study addresses the challenge of predicting the course of Adult-onset Still's disease (AoSD), a rare systemic autoinflammatory disorder of unknown origin. Precise prediction is crucial for effective clinical...
9.
Garcia-Vidal C, Teijon-Lumbreras C, Aiello T, Chumbita M, Menendez R, Mateu-Subira A, et al.
Infect Dis Ther
. 2024 Mar;
13(4):715-726.
PMID: 38489118
Introduction: The impact of remdesivir on mortality in patients with COVID-19 is still controversial. We aimed to identify clinical phenotype clusters of COVID-19 hospitalized patients with highest benefit from remdesivir...
10.
Gallardo-Pizarro A, Peyrony O, Chumbita M, Monzo-Gallo P, Aiello T, Teijon-Lumbreras C, et al.
Expert Rev Anti Infect Ther
. 2024 Mar;
22(4):179-187.
PMID: 38457198
Introduction: Artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize the management of febrile neutropenia (FN) and drive progress toward personalized medicine. Areas Covered: In this review,...